Small molecules that enhance the catalytic efficiency of HLA-DM

Journal of Immunology

Volumn 176, Issue 7, 2006, Pages 4208-4220

  Nicholson, Melissa J ^a   Moradi, Babak ^a   Seth, Nilufer P ^a   Xing, Xuechao ^b   Cuny, Gregory D ^b   Stein, Ross L ^b   Wucherpfennig, Kai W ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b The Harvard Center for Neurodegeneration & Repair   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME; HLA DM ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SMALL MOLECULE E03; SMALL MOLECULE F12; SMALL MOLECULE F15; SMALL MOLECULE M19; UNCLASSIFIED DRUG; HLA D ANTIGEN;

ANIMAL CELL; ANTIGEN FUNCTION; ANTIGEN PRESENTATION; ARTICLE; CATALYSIS; CD4+ T LYMPHOCYTE; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVITY; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; HYDROPHOBICITY; METABOLISM; MUTATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

BINDING SITES; CATALYSIS; HLA-D ANTIGENS; HUMANS; HYDROPHOBICITY; MODELS, MOLECULAR; MUTATION; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646038285     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.7.4208     Document Type: Article

References (39)

1. Mellins, E., L. Smith, B. Arp, T. Cotner, E. Cells, and D. Pious. 1990. Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes. Nature 343: 71-74.
2. Morris, P., J. Shaman, M. Attaya, M. Amaya, S. Goodman, C. Bergman, J. J. Monaco, and E. Mellins. 1994. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 368: 551-554.
3. Roche, P. A., and P. Cresswell. 1990. Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345: 615-618.
4. Germain, R. N., and A. G. Rinker, Jr. 1993. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 363: 725-728.
5. Riberdy, J. M., J. R. Newcomb, M. J. Surman, J. A. Barbosa, and P. Cresswell. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360: 474-477.
6. Denzin, L. K., and P. Cresswell. 1995. HLA-DM induces CLIP dissociation from MHC class II αβ dimers and facilitates peptide loading. Cell 82: 155-165.
7. Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. Nature 375: 802-806.
8. Weber, D. A., B. D. Evavold, and P. E. Jensen. 1996. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. Science 274: 618-620.
9. Katz, J. F., C. Stebbins, E. Appella, and A. J. Sant. 1996. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. J. Exp. Med. 184: 1747-1753.
10. Lovitch, S. B., S. J. Petzold, and E. R. Unanue. 2003. Cutting edge: H-2DM is responsible for the large differences in presentation among peptides selected by I-Ak during antigen processing. J. Immunol. 171: 2183-2186.
11. Nanda, N. K., and A. J. Sant. 2000. DM determines the cryptic and immunodominant fate of T cell epitopes. J. Exp. Med. 192: 781-788.
12. Jensen, P. E. 1992. Long-lived complexes between peptide and class II major histocompatibility complex are formed at low pH with no requirement for pH neutralization. J. Exp. Med. 176: 793-798.
13. Lanzavecchia, A., P. A. Reid, and C. Watts. 1992. Irreversible association of peptides with class II MHC molecules in living cells. Nature 357: 249-252.
14. Zarutskie, J. A., R. Busch, Z. Zavala-Ruiz, M. Rushe, E. D. Mellins, and L. J. Stern. 2001. The kinetic basis of peptide exchange catalysis by HLA-DM. Proc. Natl. Acad. Sci. USA 98: 12450-12455.
15. Chou, C. L., and S. Sadegh-Nasseri. 2000. HLA-DM recognizes the flexible conformation of major histocompatibility complex class II. J. Exp. Med. 192: 1697-1706.
16. Fremont, D. H., F. Crawford, P. Marrack, W. A. Hendrickson, and J. Kappler. 1998. Crystal structure of mouse H2-M. Immunity 9: 385-393.
17. Mosyak, L., D. M. Zaller, and D. C. Wiley. 1998. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. Immunity 9: 377-383.
18. Doebele, C. R., R. Busch, M. H. Scott, A. Pashine, and D. E. Mellins. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517-527.
19. Pashine, A., R. Busch, M. P. Belmares, J. N. Munning, R. C. Doebele, M. Buckingham, G. P. Nolan, and E. D. Mellins. 2003. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 19: 183-192.
20. Stratikos, E., L. Mosyak, D. M. Zaller, and D. C. Wiley. 2002. Identification of the lateral interaction surfaces of human histocompatibility leukocyte antigen (HLA)-DM with HLA-DR1 by formation of tethered complexes that present enhanced HLA-DM catalysis. J. Exp. Med. 196: 173-183.
21. Belmares, M. P., R. Busch, K. W. Wucherpfennig, H. M. McConnell, and E. D. Mellins. 2002. Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J. Immunol. 169: 5109-5117.
22. Smith, K. J., J. Pyrdol, L. Gauthier, D. C. Wiley, and K. W. Wucherpfennig. 1998. Crystal structure of HLA-DR2 (DRA*0101, DRB1*1501) complexed with a peptide from human myelin basic protein. J. Exp. Med. 188: 1511-1520.
23. Day, C. L., N. P. Seth, M. Lucas, H. Appel, L. Gauthier, G. M. Lauer, G. K. Robbins, Z. M. Szczepiorkowski, D. R. Casson, R. T. Chung, et al. 2003. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 112: 831-842.
24. Rosinski, M., S. Reid, and L. K. Nielsen. 2002. Kinetics of baculovirus replication and release using real-time quantitative polymerase chain reaction. Biotechnol. Bioeng. 77: 476-480.
25. Otwinowski, Z., and W. Minor. 1997. Processing of x-ray diffraction data collected in oscillation mode. In Methods in Enzymology, Vol. 276: Macromolecular Crystallography Part A. Academic, London, pp. 307-326.
26. Vagin, A., and A. Teplyakov. 1997. MOLREP: an automated program for molecular replacement. J. Appl Cryst. 30: 1022-1025.
27. Kabsch, W. 1976. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A. 32: 922-923.
28. Brunger, A. T., P. D. Adams, G. M. Clore, W. L. DeLano, P. Gros, R. W. Grosse-Kunstleve, J. S. Jiang, J. Kuszewski, M. Nilges, N. S. Pannu, et al. 1998. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54(Pt. 5): 905-921.
29. Jones, T. A., J. Y. Zou, S. W. Cowan, and M. Kjeldgaard. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47(Pt. 2): 110-119.
30. Owicki, J. C. 2000. Fluorescence polarization and anisotropy in high throughput screening: perspectives and primer. J. Biomol. Screen 5: 297-306.
31. Pin, S. S., I. Kariv, N. R. Graciani, and K. R. Oldenburg. 1999. Analysis of protein-peptide interaction by a miniaturized fluorescence polarization assay using cyclin-dependent kinase 2/cyclin E as a model system. Anal. Biochem. 275: 156-161.
32. Wucherpfennig, K. W., A. Sette, S. Southwood, C. Oseroff, M. Matsui, J. L. Strominger, and D. A. Hafler. 1994. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179: 279-290.
33. Krogsgaard, M., K. W. Wucherpfennig, B. Cannella, B. E. Hansen, A. Svejgaard, J. Pyrdol, H. Ditzel, C. Raine, J. Engberg, and L. Fugger. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191: 1395-1412.
34. Joshi, R. V., J. A. Zarutskie, and L. J. Stern. 2000. A three-step kinetic mechanism for peptide binding to MHC class II proteins. Biochemistry 39: 3751-3762.
35. Falk, K., J. M. Lau, L. Santambrogio, V. M. Esteban, F. Puentes, O. Rotzschke, and J. L. Strominger. 2002. Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. J. Biol. Chem. 277: 2709-2715.
36. Marin-Esteban, V., K. Falk, and O. Rotzschke. 2003. Small-molecular compounds enhance the loading of APC with encephalitogenic MBP protein. J. Autoimmun. 20: 63-69.
37. Fersht, A. 1984. Enzyme structure and mechanism, 2nd Ed. New York, W. H. Freeman.
38. Avva, R. R., and P. Cresswell. 1994. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1: 763-774.
39. Harrington, C. J., A. Paez, T. Hunkapiller, V. Mannikko, T. Brabb, M. Ahearn, C. Beeson, and J. Goverman. 1998. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 8: 571-580.